¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Observation for suspected toxic effect from ingested substance"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • additive effect
    ºÎ°¡È¿°ú
  • adverse effect
    À¯ÇØÈ¿°ú
  • beam hardening effect
    ºö°æÈ­È¿°ú
  • back-pressure effect
    ÈĹæ¾Ð·ÂÈ¿°ú
  • biologic effect
    »ý¹°ÇÐÀûÈ¿°ú
  • bacteriostatic effect
    Á¤±ÕÈ¿°ú
  • blow back effect
    µÞ¹Ù¶÷È¿°ú, ÈÄdzȿ°ú
  • cohort effect
    ÄÚȣƮȿ°ú
  • combined effect
    º´¿ëÈ¿°ú
  • concentration effect
    ³óµµÈ¿°ú
  • cumulative effect
    ´©ÀûÈ¿°ú, ÃàÀûÈ¿°ú
  • curative effect
    Ä¡·áÈ¿°ú
  • cytopathic effect
    ¼¼Æ÷º´º¯È¿°ú
  • carrier effect
    ¿î¹Ýüȿ°ú
  • carry-over effect
    ÀÜÈ¿
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • accelerans substance
    ÃËÁø¹°Áú
  • accessory food substance
    ºÎ¿µ¾ç¹°Áú
  • acrosomal substance
    ÷´Üü¹°Áú
  • agglutinable substance
    ÀÀÁý¼º¹°Áú
  • antibacterial substance
    Ç×±Õ¹°Áú
  • antifungal substance
    Ç×Áø±Õ¹°Áú
  • antiketogenic substance
    Ç×ÄÉÅæ»ý¼º¹°Áú
  • antithyroid substance
    Ç×¹æÆÐ»ù¹°Áú, Ç×°©»ó»ù¹°Áú
  • antiyeast substance
    Ç×È¿¸ð¹°Áú
  • blood group specific substance
    Ç÷¾×ÇüƯÀ̹°Áú
  • carcinogenic substance
    ¹ß¾Ï¹°Áú
  • cement substance
    Á¢ÇÕÁú
  • chromophil substance
    (¢¡Nissl body) ´Ö½½¼Òü
  • compact substance
    Ä¡¹ÐÁú
  • conjugated estrogenic substance
    Á¢ÇÕ¹ßÁ¤¹°Áú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • released substance
    ¹æÃâ¹°Áú(Û¯õóÚªòõ).
  • renal pressor substance
    ½Å½Â¾Ð¹°Áú(ãìã°äâÚªòõ).
  • Bernouilli effect
    º£¸£´©ÀÌ È¿°ú
  • Bohr effect
    º¸¾Æ È¿°ú(üùÍý)
  • CPE=£¾cytopathogenic effect
    ¼¼Æ÷º´º¯È¿°ú.
  • CPE=£¾cytopathogenic effect
    ¼¼Æ÷º´º¯È¿°ú.
  • Cytopath(ogen)ic effect, CPE
    ¼¼Æ÷º´º¯È¿°ú
  • Donnan effect
    µ·³­È¿°ú
  • Doppler effect
    µµÇ÷¯ È¿°ú
  • Fahraeus-Lindqvist effect
    ÆÄ·¹¿ì½º-¸°Äûºñ½ºÆ® È¿°ú(üùÍý)
  • Fenn effect
    Ææ È¿°ú(üùÍý)
  • Gibbs effect
    ±é½º È¿°ú
  • HIV effect
    HIV È¿°ú<ÀÛ¿ë>
  • Haldane effect
    ÇÒµ§È¿°ú
  • Purkinje effect
    Ǫ¸£Å°´Ï¿¡È¿°ú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • toxic delirium
    µ¶¼º¼¶¸Á(~àëØÍ).
  • toxic dementia
    Áßµ¶¼ºÄ¡¸Å(¡­öÂ?)
  • toxic diarrhea
    Áßµ¶¼º¼³»ç
  • toxic dose
    Áßµ¶(¿ë)·®(ñéÔ¸(éÄ)åÖ).
  • toxic dose
    µ¶¼º¿ë·®
  • toxic dyspepsia
    Áßµ¶¼º¼ÒÈ­ºÒ·®(ñéÔ¸àõá¼ûùÝÕåÐ)
  • toxic eczema
    Áßµ¶¼º½ÀÁø(¡­ã¥òÖ)
  • toxic edema
    Áßµ¶¼ººÎÁ¾
  • toxic epidermal necrolysis
    µ¶¼ºÇ¥ÇDZ«»ç
  • toxic epidermal necrolysis
    µ¶¼ºÇ¥ÇÇÀ¶ÇØ(Ô¸ àõøúù«ë×ú°).
  • toxic epidermal necrolysis
    µ¶¼º Ç¥ÇÇÀ¶ÇØ
  • toxic equivalent
    µ¶¼ºµî°¡¹°(Ô¸àõÔõʤڪ).
  • toxic erythema
    Áßµ¶¼ºÈ«¹Ý
  • toxic erythema
    Áßµ¶¼ºÈ«¹Ý
  • toxic erythema syndrome
    µ¶¼º È«¹Ý ÁõÈıº
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • kerr effect
    Äɸ£ È¿°ú(üùÍý)
  • kinetic isotope effect
    ¹ÝÀÀ¼Óµµ(ÚãëëáÜÓø) µ¿À§¿ø¼ÒÈ¿°ú(ÔÒêÈêªáÈüùÍý)
  • linear electric field effect
    ¼±Çü Àü±âÀåÈ¿°ú(àÊû¡ï³Ñ¨íÞüùÍý)
  • Maxwell effect
    ¸ß½º¿¤ È¿°ú(üùÍý)
  • meiotic effect
    °¨¼öºÐ¿­ È¿°ú(Êõâ¦ÝÂÖ®üùÍý)
  • neighboring group effect
    ±ÙÁ¢±â È¿°ú(ÐÎïÈÐïüùÍý)
  • oligodynamic effect
    ¹Ì·®ÀÛ¿ëÈ¿°ú(Ú°ÕáíÂéÄüùÍý)
  • opsonic effect
    ¿É¼Ò´Ñ È¿°ú(üùÍý)
  • orientation effect
    Á¤À§ È¿°ú(ïÒêÈüùÍý)
  • Pasteur effect
    ÆÄ½ºÅ𸣠ȿ°ú(üùÍý)
  • phospholipid effect
    ÀλêÁöÁúÈ¿°ú(×òß«ò·òõüùÍý)
  • photochemical effect
    ±¤È­ÇÐÈ¿°ú(ÎÃûùùÊüùÍý)
  • photoelectric effect
    ±¤ÀüÈ¿°ú(ÎÃï³üùÍý)
  • piezoelectric effect
    ¾ÐÀü±âÈ¿°ú(äâï³Ñ¨üùÍý)
  • pressor effect
    Ç÷¾Ð È¿°ú(úìäâüùÍý)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • spin phase effect
    ½ºÇÉÀ§»óÈ¿°ú
  • T1 shortening effect
    T1´ÜÃàÈ¿°ú
  • T2 shortening effect
    T2´ÜÃàÈ¿°ú
  • volume averaging effect
    ¿ëÀûÆò±ÕÈ­È¿°ú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
NOSIE Nurses' Observation Scale for Inpatient Evaluation
O&A observation and assessment
Obs observation, observed; obstetrics, obstetrician
OCU observation care unit
O&E observation and examination
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
TSST-1 Toxic Shock Syndrome Toxin-1
TA Toxic adenoma
TSST Toxic shock syndrome toxin
TSLS Toxic shock-like syndrome
DTG diffuse toxic goiter
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • white substance
    ¹é»ö Áú
  • additive effect
    ÷°¡ È¿°ú, »óÇÕÈ¿°ú
    ¼­·Î ´Ù¸¥ µÎ ¾à¹°À» ¾î´À Á¤µµ±îÁöÀÇ ¿ë·® ¹üÀ§ ³»¿¡¼­ µ¿½Ã¿¡ Åõ¿©ÇÒ °æ¿ì ±× È¿°ú´Â µÎ ¾à¹°À» °¢°¢ ´Üµ¶À¸·Î Åõ¿©ÇÏ¿´À» ¶§ ³ªÅ¸³ª´Â ÀÛ¿ëÀÇ »ê¼úÀûÀÎ ÇÕ¸¸À¸·Î ³ªÅ¸³ª´Â ÀÛ¿ë.
  • adrenal suppressive effect
    ºÎ½Å ¾ïÁ¦ È¿°ú
  • air gap effect
    °ø±â °£°Ý È¿°ú
  • allogenic effect
    µ¿Á¾ ¼¼Æ÷ ¹ÝÀÀ È¿°ú
    µ¿Á¾ÀÇ ¸²ÇÁ°í¸¦ Åõ¿©ÇÔÀ¸·Î½á ºñƯÀÌÀûÀ¸·Î ¸é¿ª¹ÝÀÀÀÌ Áõ°¡µÇ±âµµ ÇÏ°í ¾ïÁ¦µÇ±âµµ ÇÏ´Â Çö»ó. Áõ°¡µÈ °æ¿ì¸¦ Á¤ÀÇ allogenic È¿°ú, ¾ïÁ¦µÈ °æ¿ì¸¦ ºÎÀÇ allogenic È¿°ú¶ó°í ÇÑ´Ù.
  • anticurare effect
    Ç×Å¥¶ó·¹ ÀÛ¿ë
  • antitussive effect
    ÁøÇØ È¿°ú
  • autonomic effect
    ÀÚÀ² ½Å°æ¼º È¿°ú, ÀÚÀ² ½Å°æ È¿°ú
  • balloning effect
    ÆØÃ¢ È¿°ú
  • Bernouilli effect
    º£¸£´©ÀÌ È¿°ú
  • biological effect
    »ý¹°ÇÐÀû È¿°ú
  • blanching effect
    Ç¥¹é È¿°ú
  • blocking effect
    Â÷´Ü È¿°ú
  • carriar effect
    ´ãü È¿°ú
    Ha
  • carry effect
    ¿î¹Ý È¿°ú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
vasodepressor substance An incompletely characterised chemical, apparently produced during liver damage, that tends to decrease vascular pressures and relax arterial walls.
(05 Mar 2000)
gelatinous substance The apical part of the posterior horn (dorsal horn; posterior gray column) of the spinal cord's gray matter, composed largely of very small nerve cells; its gelatinous appearance is due to its very low content of myelinated nerve fibres.
Synonym: substantia gelatinosa, Rolando's gelatinous substance, Rolando's substance.
(05 Mar 2000)
glandular substance of prostate The glandular tissue of the prostate as distinct from the stroma and capsule.
Synonym: substantia glandularis prostatae.
(05 Mar 2000)
Reichstein's substance One of several steroids; e.g., Reichstein's substance F (cortisone), Reichstein's substance H (corticosterone), Reichstein's substance M (cortisol), Reichstein's substance Q (cortexone), and Reichstein's substance S (cortexolone).
Synonym: Reichstein's compound.
(05 Mar 2000)
released substance <haematology> A polysaccharide precursor molecule which is used to make the antigens on the surface of human blood cells that are classified in the ABO blood group system.
(09 Oct 1997)
central and lateral intermediate substance The central gray matter of the spinal cord surrounding the central canal.
Synonym: substantia intermedia centralis et lateralis, anterior gray column, Stilling's gelatinous substance, substantia gelatinosa centralis.
(05 Mar 2000)
central gray substance In general: the predominantly small-celled gray matter adjoining or surrounding the central canal of the spinal cord and the third and fourth ventricles of the brainstem, in particular: the thick sleeve of gray matter surrounding the cerebral sylvian aqueduct in the midbrain, rostrally continuous with the posterior nucleus of the hypothalamus; in sections stained for myelin it stands out from the adjoining tectum and tegmentum by the poverty of its myelinated fibres.
Synonym: substantia grisea centralis.
(05 Mar 2000)
medullary substance The lipid material present in the myelin sheath of nerve fibres.
Synonym: Schwann's white substance.
(05 Mar 2000)
reticular substance A filamentous plasmatic material, beaded with granules, demonstrable by means of vital staining in the immature red blood cells.
Synonym: alpha substance, filar mass, filar substance, substantia reticularis, substantia reticulofilamentosa.
Synonym: reticular formation.
(05 Mar 2000)
gray substance The cortex of the brain which contains nerve cell bodies. The gray matter is in contrast to the white matter, the part of the brain that contains myelinated nerve fibres. The gray matter is so named because it in fact appears gray. The white matter is white because that is the colour of myelin, the insulation covering the nerve fibres. In the mysterious affair at styles (1920), agatha christie first quoted the fictional belgian detective hercule poirot in regard to his gray matter: 'this affair must be unravelled from within.' he tapped his forehead. 'these little grey cells. It is up to them as you say over here.'
(12 Dec 1998)
ground substance The amorphous material in which structural elements occur; in connective tissue, it is composed of proteoglycans, plasma constituents, metabolites, water, and ions present between cells and fibres.
Synonym: substantia fundamentalis.
(05 Mar 2000)
growth substance <biology, cell biology> Signal molecules that are involved in the control of cell growth and differentiation.
(12 Dec 1998)
Rolando's gelatinous substance The apical part of the posterior horn (dorsal horn; posterior gray column) of the spinal cord's gray matter, composed largely of very small nerve cells; its gelatinous appearance is due to its very low content of myelinated nerve fibres.
Synonym: substantia gelatinosa, Rolando's gelatinous substance, Rolando's substance.
(05 Mar 2000)
chromidial substance Endoplasmic reticulum in which ribosomal granules are applied to the cytoplasmic surface of the cisternae; involved in the synthesis and secretion of protein via membrane-bound vesicles to the extracellular space.
Synonym: chromidial substance, ergastoplasm, rough-surfaced endoplasmic reticulum.
(05 Mar 2000)
chromophil substance The material consisting of granular endoplasmic reticulum and ribosomes that occurs in nerve cell bodies and dendrites.
Synonym: basophil substance, basophilic substance, chromophil substance, Nissl bodies, Nissl granules, substantia basophilia, tigroid bodies, tigroid substance.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á